Portage Biotech Inc. announced that Dr. Ian Walters, Chief Executive Officer of Portage, will be appointed Chairman of Portage's Board of Directors. Dr. Greg Bailey, current Chairman, will transition to lead Director. Additionally, the company hired Justin Fairchild, MPH, as Vice President of Development.

"The changes reflect the Board's confidence and acknowledgement of Portage's recent growth and progress under Dr. Walters' leadership," remarked Dr. Bailey. He will assist Dr. Walters in advancing Portage's pipeline of novel immunotherapy treatments, including the ongoing Phase 1/2 study of the iNKT agonist PORT-2 and the planned trials for adenosine inhibitors PORT-6 and PORT- 7, both of which have been cleared by the FDA to enter clinical studies. Mr. Fairchild has nearly 20 years of experience advancing oncology programs through the clinic, including his prior role at The Parker Institute and 14 years at Bristol Myers Squibb, where he held several roles in clinical development and contributed to both early- and late-stage studies of multiple targeted and immunotherapy oncology agents.

He earned his MPH from The Johns Hopkins School of Public Health and a B.A. in Chemistry from Colgate University.